MedTrace Logo

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes

NCT00612040 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 178

Last updated 2017-03-03

Study results available
· View outcomes & findings →

Summary

This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of this trial is to compare two NN1250 (insulin degludec) formulations with each other and with insulin glargine, all in combination with insulin aspart in subjects with type 1 diabetes.

Conditions

Interventions

DRUG

insulin degludec

Formulation 1: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily

DRUG

insulin degludec

Formulation 2: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily

DRUG

insulin glargine

Treat-to-target dose titration scheme, injection s.c., once daily

DRUG

insulin aspart

Treat-to-target dose titration scheme, injection s.c. (under the skin), 3 times daily

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States
  • Australia
  • Germany
  • Norway
  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00612040 on ClinicalTrials.gov